AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biotechnology company focused on innovative mental health treatments. Following its 2025 strategic combination and redomiciliation, the company is advancing key programs, including BPL-003 nasal spray for treatment-resistant depression (TRD).
Financial performance showed revenue growth to ~$1.07 million in Q4, with adjusted EPS beating estimates (though GAAP results reflected merger impacts). The company is on track to initiate a Phase 3 pivotal program for BPL-003 in Q2 2026, consisting of two trials (ReConnection-1 and ReConnection-2) targeting adults with TRD, following positive FDA End-of-Phase 2 feedback.
Despite ongoing unprofitability (negative P/E, negative operating cash flow), low debt and high liquidity support continued development. Other progress includes positive Phase 2a results for EMP-01 in Social Anxiety Disorder. The company discussed these updates during its Virtual Investor Day on March 6, 2026.